PO.CH01.02 · 化学

患者来源结直肠癌类器官中化合物反应的自动化培养和AI辅助图像分析

Automated culture and AI-enabled image analysis of compound responses in patient-derived colorectal cancer organoids

海报缩略图:患者来源结直肠癌类器官中化合物反应的自动化培养和AI辅助图像分析
编号 6419 展板 19 时间 4/21 02:00–05:00 区域 Section 39 主讲 Oksana Sirenko, PhD
分会场 Screening and Technology Advances for Probe and Drug Discovery
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Oksana Sirenko1, Prathyushakrishna Macha1, Zhisong Tong1, Nikki Carter2, Felix Spira1

1Molecular Devices, LLC, San Jose, CA,2Molecular Devices, LLC (Moldev), San Jose, CA

摘要 Abstract

中文摘要
类器官通过提供生理相关的模型改变了生物医学研究,这对于研究疾病机制和药物反应至关重要。然而,手动的类器官培养过程劳动强度大且容易产生变异性,限制了其广泛应用。此外,从复杂生物系统中提取信息仍是类器官研究中的一大挑战。在此,我们展示了使用患者来源类器官进行自动化培养、扩增和终点检测的方法开发,并结合机器学习方法进行基于图像的化合物反应分析。患者来源的结直肠癌(CRC)类器官使用CellXpress.ai自动化细胞培养系统在Matrigel穹顶中培养,该系统能够实现自动化的接种、换液、成像和传代。成像和换液按周期设定,而传代则由用户触发或基于图像分析和类器官表型自动进行。使用该系统,我们成功维持类器官培养超过一个月,并将其扩增至足以用于多个96孔检测板的数量。培养的类器官用一组代表多种作用机制的抗癌药物进行处理。使用自动化共聚焦高内涵成像评估对类器官形态和细胞活力的剂量依赖性效应。药物处理后,类器官或用活力染料进行活体染色,或固定后用一组针对细胞核、细胞骨架、线粒体和RNA含量的标志物进行染色。使用IN Carta分析软件中的深度学习模型分析图像。机器学习工具通过自动识别类器官并将其评分为完整或受损,提供了一种无偏且全面的分析方法。分析方案为每个类器官提取了一组定量特征。这些特征包括形态学描述符、三个荧光通道的强度指标、纹理特征和空间分布模式。提取这些特征能够对类器官群体进行多维表型分析。分类采用无监督和有监督机器学习相结合的方式进行。无监督聚类根据特征相似性将类器官分组为表型簇,然后使用用户定义的标准将其整理为具有生物学意义的类别。该分类能够以浓度依赖的方式评估化合物效应。与单参数读出不同,该方法纳入了广泛的形态学背景。总之,我们展示了一个使用3D人类类器官评估化合物效应的全自动化工作流程。所述方法能够实现AI驱动的表型分析,用于评估类器官模型中的药物诱导效应。
查看英文原文 English abstract
Organoids transformed biomedical research by providing physiologically relevant models for cancer studies, essential for investigating disease mechanisms and drug responses. However, manual organoid culture processes are labor-intensive and prone to variability, limiting widespread adoption. Additionally, extracting information from complex biological systems remains a major challenge in organoid research. Here, we present the development of methods for automated culture, expansion, and end-point assays using patient-derived organoids, combined with machine-learning approaches for image-based analysis of compound responses. Patient-derived colorectal cancer (CRC) organoids were cultured in Matrigel domes using the CellXpress.ai automated cell culture system, which enables automated seeding, media exchanges, imaging, and passaging. Imaging and media exchanges were set periodically, while passaging was either triggered by users or automatically, based on image analysis and phenotypes of organoids. Using this system, we successfully maintained organoid cultures for over a month and expanded them to quantities sufficient for multiple 96-well assay plates. Cultured organoids were treated with a panel of anti-cancer drugs representing diverse mechanisms of action. Dose-dependent effects on organoid morphology and cell viability were evaluated using automated confocal high-content imaging. Following drug treatment, organoids were either stained live with viability dyes or fixed and stained with a panel of markers for nuclei, cytoskeleton, mitochondria, and RNA content. Images were analyzed using a deep learning model in IN Carta analysis software. Machine learning tools offer an unbiased and comprehensive approach to analysis by automatically identifying organoids and scoring them as intact or damaged. The analysis protocol extracted a panel of quantitative features per organoid. These included morphological descriptors, intensity metrics across three fluorescent channels, textural features, and spatial distribution patterns. Features were extracted enabling multidimensional phenotypic profiling of organoid populations. Classification was performed using a combination of unsupervised and supervised machine learning. Unsupervised clustering grouped organoids into phenotypic clusters based on feature similarity, which were then curated into biologically relevant categories using user-defined criteria. The classification allowed evaluation of compound effects in a concentration-dependent manner. Unlike single-parameter readouts, this approach incorporates a broad morphological context. In summary, we demonstrated a fully automated workflow for evaluation of compound effects using 3D human organoids. The described approach enables AI-driven phenotypic profiling for assessing drug-induced effects in organoid models.
利益披露 Disclosure
O. Sirenko, Molecular Devices Employment. P. Macha, Molecular Devices Employment. Z. Tong, Molecular Devices Employment. F. Spira, Molecular Devices Employment.

← 返回 AACR 2026 检索